TRUE Private Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

TRUE Private Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$210K	Sell	424 -257	-38%	-$114K	0.02%	266
2026 Q1	$304K	Buy	681 +5	+0.7%	+$2.33K	0.03%	216
2025 Q4	$306K	Sell	676 -164	-20%	-$70.7K	0.03%	208
2025 Q3	$329K	Sell	840 -105	-11%	-$43.9K	0.03%	199
2025 Q2	$421K	Sell	945 -1	-0.1%	-$461	0.05%	168
2025 Q1	$459K	Buy	+946	New	+$441K	0.06%	138
2021 Q1	–	Sell	-17	Closed	-$4K	–	689
2020 Q4	$4K	Hold	17	–	–	﹤0.01%	624
2020 Q3	$4K	Hold	17	–	–	﹤0.01%	590
2020 Q2	$4K	Buy	+17	New	+$4.61K	﹤0.01%	589
2020 Q1	–	Sell	-852	Closed	-$186K	–	843
2019 Q4	$186K	Buy	+852	New	+$172K	0.03%	227
2019 Q3	–	Sell	-852	Closed	-$156K	–	699
2019 Q2	$156K	Buy	+852	New	+$149K	0.03%	224
2018 Q4	–	Sell	-876	Closed	-$169K	–	891
2018 Q3	$169K	Buy	+876	New	+$156K	0.02%	285

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

TRUE Private Wealth Advisors's VRTX Position: Q2 2026 in Review

TRUE Private Wealth Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 38% in Q2 2026, selling an estimated $114K and leaving 424 shares worth $210K. The position accounts for 0.02% of the portfolio, ranked #266.

TRUE Private Wealth Advisors first reported a position in VRTX in Q3 2018 and has held it in 12 quarters since. The position peaked at $459K in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

TRUE Private Wealth Advisors held 424 shares of Vertex Pharmaceuticals worth $210K as of Q2 2026.
TRUE Private Wealth Advisors sold 257 Vertex Pharmaceuticals shares in Q2 2026, an estimated $114K.
Vertex Pharmaceuticals made up 0.02% of TRUE Private Wealth Advisors's portfolio in Q2 2026, its #266 holding.
TRUE Private Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 12 quarters since.
TRUE Private Wealth Advisors's Vertex Pharmaceuticals position peaked at $459K in Q1 2025.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on TRUE Private Wealth Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.